Related Experiment Videos
Rhabdomyosarcoma treated with chemotherapy during the third trimester
D Martin1, S S Winter, M O Gardner
1Department of Obstetrics and Gynecology, School of Medicine, University of New Mexico Health Science Center, Albuquerque, USA.
Obstetrics and Gynecology
|May 1, 1997
Summary
Chemotherapy effectively treated aggressive rhabdomyosarcoma in a pregnant patient, showing no adverse fetal complications. This highlights chemotherapy
Area of Science:
- Oncology
- Maternal-Fetal Medicine
Background:
- Rhabdomyosarcoma is a rare and aggressive tumor during pregnancy.
- Standard treatment involves multiagent chemotherapy, posing maternal-fetal risks.
Observation:
- A case of stage III facial rhabdomyosarcoma in an 18-year-old pregnant woman.
- Diagnosis occurred in the third trimester of pregnancy.
Findings:
- The patient achieved clinical remission with multiagent chemotherapy during pregnancy.
- No fetal complications were observed during or after treatment.
Implications:
- Chemotherapy is a crucial frontline treatment for pregnant women with rhabdomyosarcoma.
- Effective chemotherapy can lead to successful remission without compromising fetal health.